Pilsicainide HCl

Research use only, not for human use.

Pilsicainide HCl is a pure sodium channel blocker.

Pilsicainide HCl is a pure sodium channel blocker.(In Vitro):Pilsicainide hydrochloride (SUN-1165) (10-200 μg/mL) decreases peak amplitude of the net inward current in a dose-dependent manner with an IC50 of 29.2 ± 22.9 μg/mL in levo-thyroxine (T4)-treated rat atrial cells.(In Vivo):Pilsicainide hydrochloride (SUN-1165) (2 mg/kg; i.v.; once) decreases the conduction velocity in T4-treated rat atrium by decreasing the Max dV/dt and net inward current.

Pilsicainide hydrochloride (SUN-1165) (10-200 μg/mL) decreases peak amplitude of the net inward current in a dose-dependent manner with an IC50 of 29.2 ± 22.9 μg/mL in levo-thyroxine (T4)-treated rat atrial cells.

Pilsicainide hydrochloride (SUN-1165) (2 mg/kg; i.v.; once) decreases the conduction velocity in T4-treated rat atrium by decreasing the Max dV/dt and net inward current. Animal Model:Male Sprague-Dawley (SD) rats weighing from 200 to 220 g, with levo-thyroxine (T4) treatmentDosage:2 mg/kg Administration:Bolus injection into right external carotid vein within 2 minutes, once Result:Result: the QT interval was significantly elongated at 15 and 60 minutes after administration. P wave and QRS complex durations were significantly shortened. Markedly decreased action potential amplitudes (APA) and Max dV/dt, and significantly lengthened the action potential durations.

SUN 1165

Membrane Transporter/Ion Channel

Sodium Channel

Sodium Channel

Cardiovascular Disease

Paroxysmal Atrial Fibrillation

88069-49-2

308.85

C17H25ClN2O?

>98% (HPLC)

In Vitro:?DMSO : 50 mg/mL (161.89 mM)

Cc1cccc(C)c1NC(=O)CC12CCCN1CCC2.Cl

——

(-20℃)

With Ice Pack

≥ 2 years